All In Biotech

NDA 211617 · Esperion Theraps INC

Nexlizet

Bempedoic Acid, Ezetimibe · Oral · Adenosine Triphosphate-Citrate Lyase Inhibitor; Dietary Cholesterol Absorption Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Feb 26, 2020

Approved uses

4

Original approval plus efficacy supplements

Registered trials

44

16 Phase 3, 11 recruiting

FAERS reports

719

155 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 25, 2026.

NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Bempedoic acid, a component of NEXLIZET, is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin). NEXLIZET, a combination of bempedoic acid, an adenosine triphosphate citrate lyase (ACL) inhibitor, and ezetimibe, a dietary cholesterol absorption inhibitor, is indicated: As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). ( 1 ) Bempedoic acid, a component of NEXLIZET, is indicated: To reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin). ( 1 )

Mechanism: NEXLIZET contains bempedoic acid and ezetimibe. NEXLIZET reduces elevated LDL-C through inhibition of cholesterol synthesis in the liver and absorption in the intestine. Bempedoic acid Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 21, 2025 Supplement 29 · Efficacy LetterLabel
  • Mar 22, 2024 Supplement 16 · Efficacy LetterLabel
  • Mar 22, 2024 Supplement 17 · Efficacy LetterLabel
  • Feb 26, 2020 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLabelLetterReview
1 products under this application
  • NEXLIZET · BEMPEDOIC ACID 180MG; EZETIMIBE 10MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bempedoic Acid" as an intervention, any sponsor and status, largest first.

All 44 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myalgia62
  • arthralgia60
  • pain in extremity47
  • fatigue38
  • muscle spasms36
  • headache31
  • back pain30
  • diarrhoea29
  • pain27
  • dizziness26
  • product dose omission issue26
  • drug ineffective24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
202042
2021135
202293
202341
202493
2025171
2026143

Recalls

2 FDA enforcement reports for this application.

  • Mar 27, 2024 · Class III · Completed

    Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.

  • Aug 16, 2023 · Class III · Terminated

    Failed dissolution specifications: below specification results at stability 12-month

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nexlizet (Bempedoic Acid/Ezetimibe)

2024 spending

$70.8M

Beneficiaries

27,149

97,223 claims

Per beneficiary

$2,609

$13.07 per unit

View as table
YearSpending
2020$1,731,348
2021$15,279,848
2022$30,499,194
2023$46,922,023
2024$70,824,598

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 84 on PubMed

Sponsor: Esperion Theraps INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.